Ishares Core EURO STOXX 50 UCITS ETF
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Euro Stoxx 50® Index
MARKET-LINKED PRODUCTS UNDERLIER: EURO STOXX 50® INDEX Market-Linked Products, considered complex investments, are linked to the performance of an underlying asset, such as the EURO STOXX 50® Index (“Index”). Dividends paid on the underlier are not passed through to the Market- Linked Product. If held to maturity, any potential coupon payments or gains will be paid out based on the performance of the Index, as detailed in the offering documents. Additionally, your statement value will reflect any upward or downward movements in the volatility of the Index. ® EURO STOXX 50 Index – Historical Look at Gains & Losses The chart below illustrates the number of times the Index’s return, measured from the beginning to the end of different time periods within the past 20 years, landed within various return ranges. Total Rolling Total Total 0 to -6 to -11 to -16 to -21 to -26 to -31 to -36 to 0% to 11 to 21 to 31 to Periods Gains Losses -5% -10% -15% -20% -25% -30% -35% -40% < -40% 10% 20% 30% 40% > 40% 1-Yr 229 131 98 16 17 14 16 11 7 4 5 8 46 63 16 5 1 3-Yr 205 113 92 14 11 10 11 9 7 13 10 7 31 29 10 10 33 5-Yr 181 105 76 10 6 9 11 13 9 1 1 16 25 20 15 23 22 7-Yr 157 89 68 5 4 5 8 11 24 7 2 2 26 17 17 15 14 10-Yr 121 65 56 3 6 4 9 15 1 8 9 1 16 23 14 7 5 The chart below illustrates the percentage of times1 (based on total rolling periods) the Index’s return, measured from the beginning to the end of different time periods within the past 20 years, landed within various return ranges. -
Annual Report 2019 Contains a Full Overview of Its Corporate Stakeholder Expectations As Well As Long-Term Trends Governance Practices
Table of Contents Management report Company overview ............................................................................................................................................................................... 4 Business overview ................................................................................................................................................................................ 5 Disclosures about market risk ............................................................................................................................................................... 44 Group organizational structure ............................................................................................................................................................. 47 Key transactions and events in 2019 .................................................................................................................................................... 50 Recent developments ........................................................................................................................................................................... 53 Research and development .................................................................................................................................................................. 54 Sustainable development .................................................................................................................................................................... -
Dow Jones STOXX Indices Rulebook
Dow Jones STOXX® Index Guide Version 13.0 · October 2008 ® DOW JONES STOXX INDEX GUIDE Section A: Dow Jones STOXX Equity Indices 3 Section B: Dow Jones STOXX Strategy Indices 70 Section C: Industry Classifi cation Benchmark 89 Changes to the Dow Jones STOXX Index Guide 100 STOXX LIMITED A Joint Venture of Deutsche Börse AG, Dow Jones & Company and SIX Swiss Exchange AG The indices described in this guide are the intellectual property of STOXX Limited and/or Dow Jones & Company Inc. ‘STOXX’ is a registered trademark of STOXX Limited. ‘Dow Jones’ and ‘Dow Jones Indexes’ are service marks of Dow Jones & Company Inc. A licence agreement is required to use indices and trademarks from STOXX and/or Dow Jones Indexes for any commercial purpose, namely but not exclusively for arranging, marketing, issuing, promoting fi nancial products based on the indices. Neither STOXX nor Dow Jones sells, sponsors or recommends the purchase of fi nancial products based on their indices. Neither Dow Jones nor STOXX makes any warranty as to the accuracy and completeness of any such index or any information related to it, or, as to the results to be obtained by any person or entity from the use of any such index or any information related to it. www.stoxx.com 2 DOW JONES STOXX® INDEX GUIDE Section A: Dow Jones STOXX Equity Indices www.stoxx.com 3 ® DOW JONES STOXX INDEX GUIDE Section A 1 OVERVIEW 6 4 DEFINITIONS 28 1.1 Index Family 6 4.1 Base Dates & Base Values 28 1.2 Coverage 8 4.2 Block Ownership & Restricted Shares 29 1.2.1 Global 8 4.3 Free Float Market Capitalisation 30 1.2.2 Europe 9 4.4 Weighting Factors 30 1.2.3 Eastern Europe 10 4.5 Weighting Cap Factors 31 4.6 Buffers 32 4.7 Currency Rates 32 2 SCOPE 11 4.8 Dividend Treatment 33 2.1 Investable Stock Universe 11 4.9 Index Parameters 33 2.2 Stock Exchanges and Trading Systems 11 4.9.1 Price & Total Return Indices 33 2.2.1 Global 11 4.9.2 Indices in Euro, U.S. -
2020 Notice of Annual General Meeting and Proxy Statement
Notice of 2020 Annual General Meeting of Shareholders and Proxy Statement Making our world more productive 2019 Key Board Actions The Board and its committees undertook the A Message from following key actions during 2019: Our Chairman • Oversaw the Company’s capital allocation strategy, with a focus on investment for future growth and appropriate shareholder distribution levels (including declaration of Dear fellow shareholders, an initial cash dividend and subsequent On behalf of Linde’s entire Board of Directors, I am approval of a 10% increase for 2020) pleased to invite you to the second Annual General • Approved an executive compensation Meeting of Shareholders (“AGM”) of Linde plc program that reflects a clear pay-for- (“Linde” or the “Company”). performance philosophy and aligns management’s interests with those of COVID-19 Pandemic shareholders (please see the detailed We find ourselves in the midst of a global discussion of the executive compensation pandemic of unparalleled proportions. The Board program in the accompanying proxy of Directors is actively monitoring ongoing statement). developments and providing advice and counsel to • Conducted the Company’s initial strategy management as the Company seeks to mitigate and enterprise risk assessment reviews, the impact of the COVID-19 health crisis on our critical topics over which the Board will employees, business, customers and communities. continue to exercise appropriate oversight going forward. Undertook a talent review which As we do this, we adhere to safety as one of • underscored the strength and depth of our Linde’s core corporate values and this includes the global human capital. health and safety of our shareholders. -
REFERENCE DOCUMENT Including the Sustainable Development Report Contents
2015 REFERENCE DOCUMENT Including the Sustainable Development Report Contents Key Figures 2 1 Management Report 9 4 Financial statements 199 History of the Air Liquide Group 10 Consolidated fi nancial statements 201 Activities and risk factors 15 Statutory accounts of the parent company 275 2015 Performance 32 Investment cycle and fi nancing strategy 45 Innovation 53 Strategy and outlook 62 5 Annual General Meeting 2016 297 Board of Directors’ Report on the resolutions presented to the 2016 Combined Shareholders’ 2 2015 Corporate Social Responsibility Meeting 298 and Sustainable Development Report 65 Resolutions presented for the approval of the Combined Shareholders’ Meeting – Introduction 66 May 12, 2016 307 Our 2015 Social and Environmental Contribution 67 Statutory Auditors’ Reports 327 Environmental, social and governance (ESG) report 69 Reporting methodology 113 Independent verifi er’s report 115 Appendix 118 6 Additional information 339 Share capital 340 General information 346 3 Corporate governance 119 Trade payables 356 Factors that may have an impact in the event Management and control 120 of a takeover bid 357 Report from the Chairman of the Board of Directors 123 Person responsible for the Reference Document 359 Remuneration of the Executive Offi cers and Directors Cross-reference table for the Reference Document 360 of L’Air Liquide S.A. 147 Cross-reference table for the Annual Financial Report 364 Statutory Auditors’ Report 174 Cross-reference table for the Management Report 365 Transactions involving Company shares performed -
Euronext Single Stock Dividend Futures: the Widest Choice of Contracts
DIVIDEND DERIVATIVES: PLAY THE DIVIDEND FIELD WITH EURONEXT EURONEXT SINGLE STOCK DIVIDEND FUTURES: THE WIDEST CHOICE OF CONTRACTS September 2019 EURONEXT SSDFS: THE WIDEST CHOICE OF CONTRACTS 1st Dividend Exchange by number of contracts Number of contracts per country of underlying Number Number of SSDFs Underlyings ▪ Euronext began developing the range in of SSDFs only on Euronext Italy 24 11 January 2015 and regularly issues contracts Germany 27 0 to satisfy the needs of end-users Netherlands 23 9 ▪ We have nearly 300 SSDF contracts tradable Belgium 15 14 with the most diversified underlyings from Portugal 3 3 France 47 7 across Europe and the USA. Ireland 1 0 ▪ Investors can access dividend contracts on UK 36 10 new underlyings, as a total of 117 SSDFs are Spain 22 10 only available at Euronext exclusively. USA 57 36 Finland 7 2 Sweden 13 12 Norway 2 2 Switzerland 18 0 Austria 1 1 │ 2 INTRODUCTION OF SEMI-ANNUAL MATURITIES Euronext introduced semi-annual maturities on a range of Single Stock Dividend Futures listed on the Paris Derivatives Market, which offer new trading opportunities to market participants by helping them target dividend distributions more accurately on most traded names (see below). For these underlyings, the maturities available are 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months. UNDERLYING ISIN CODE TRADING SYMBOL 1 Sanofi FR0000120578 SA8 2 BNP Paribas FR0000131104 BN8 3 AXA FR0000120628 CS8 4 Air Liquide FR0000120073 AI8 5 Orange SA FR0000133308 FT8 6 Vinci SA FR0000133308 DG8 7 LVMH FR0000121014 MC8 8 ENGIE -
Prospectus Sicav Bnp Paribas Easy Fr
PROSPECTUS SICAV BNP PARIBAS EASY FR A SICAV (OPEN-ENDED COLLECTIVE INVESTMENT SCHEME) COVERED BY EUROPEAN DIRECTIVE 2009/65/EC 1 PROSPECTUS – SICAV BNP PARIBAS EASY FR I- GENERAL CHARACTERISTICS I.1 - FORM OF THE UCITS NAME: BNP PARIBAS EASY FR LEGAL FORM AND MEMBER STATE IN WHICH THE UCITS WAS ESTABLISHED: A French société d investissement à capital variable (hereafter the "SICAV") having its registered office at 1, boulevard Haussmann, 75009 PARIS, registered at the Paris Trade and Companies Registry (RCS). CREATION DATE AND INTENDED LIFETIME: The SICAV was created on 16 September 2013 for a term of 99 years. FUND OVERVIEW: BNP PARIBAS EASY STOXX EUROPE 600 UCITS ETF: MINIMUM MINIMUM CURRENCY LISTING INITIAL NET ALLOCATION SUBSCRIPTION AMOUNT OF OF SUBSCRIBERS EXCHANGE NAME ASSET ISIN CODES OF DISTRIBUTABLE AMOUNT PURCHASES/SAL DENOMIN CONCERNED (SECONDARY VALUE AMOUNTS (PRIMARY ES (SECONDARY ATION MARKET) MARKET) MARKET) EUR 2 million EUR EURONEXT apart from 36.3757 PARIS companies of All the BNP EUR C (Divided FR0011550193 Accumulation EUR subscribers ONE UNIT XETRA Paribas by 5 on 8 Group and June authorised SIX SWISS 2018) participants EXCHANGE EUR EUR 2 million EURONEXT 100.000 apart from PARIS 0 Accumulation companies of All EUR C/D FR0011550672 and/or EUR the BNP ONE UNIT XETRA (Divided subscribers Distribution Paribas Group by 14 on and authorised 8 June SIX SWISS participants 2018) EXCHANGE BNP PARIBAS EASY S&P 500 UCITS ETF: MINIMUM MINIMUM CURRENCY LISTING ALLOCATION SUBSCRIPTION AMOUNT OF INITIAL NET OF SUBSCRIBERS EXCHANGE -
In EURO STOXX 50®
EURO STOXX 50® ESG Futures & Options Launch date 9 Nov 2020 August 2021 EURO STOXX® 50 ESG Futures & Options Eurex has been the first exchange establishing ESG versions of major European benchmarks ▪ The product suite offers a hedging alternative to existing benchmarks ▪ Expanding product suite to the most liquid benchmark(s) incorporating ESG ▪ Strong support by Market Makers and Banks onscreen and off-book, as demand in ESG increases as a general investment approach ▪ Better performance of ESG also during the COVID19 market turbulence ▪ Incorporating ESG means lowering the risk ▪ Easy and understandable index concept ▪ The indexes incorporate the broadest exclusions while seeking to maintain a profile similar to market cap indexes ▪ Screening of the minimum standards / ESG screen1) ▪ Weight selected securities by free-float market capitalization ▪ Fast Exit Rule 1) (As identified by Sustainalytics. Additionally, companies w hich do not have product involvement data are not considered for selection. Companies w ith no ESG scores are assigned a zero score) 2 August 2021 Internal Development EURO STOXX 50 STOXX EURO Development Capitalised Volume in M. EUR 1,000,000 1,500,000 2,000,000 2,500,000 500,000 0 Nov-10 Feb-11 May-11 Aug-11 Nov-11 Feb-12 May-12 Capitalized Volume in EUR Volume Capitalized Aug-12 Nov-12 Feb-13 May-13Maker Market Aug-13 Nov-13 Feb-14 May-14 Agent Aug-14 Nov-14 Feb-15 May-15 Aug-15 Nov-15 Capitalized Open Interest Adjusted in EUR Interest Adjusted Open Capitalized Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Internal Feb-18 May-18 ® 3 Aug-18 Nov-18 (FESX) Futures Feb-19 May-19 Aug-19 Nov-19 Feb-20 May-20 Aug-20 Nov-20 Feb-21 May-21 Aug-21 0 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 Capitalised Open Interest in M. -
Letter to Shareholders April 2021
LETTER TO SHAREHOLDERS APRIL 2021 P. 2 — RESULTS P. 4 — COVID-19 P. 6 — CMD21 P. 8 — SHAREHOLDER INFORMATION RESULTS MESSAGE FROM FULL-YEAR 2020 THE CHAIRMAN RESULTS Business net Company sales1 income1 €36,041m €7,347m +3.3% (-0.2%) +9.6% (+4.2%) Serge Weinberg, Chairman of the Board of Directors Business EPS 1 , 2 2020 dividend3 Dear shareholders, Summarizing 2020 in a few words is difficult. The progress Sanofi has €5,86 €3.20 made in this first year of execution of the new strategy presented in +9.2% (+3.9%) per share December 2019 is very real. Our Research and Development pipeline is improving and the global business units are refocusing on their core activities. More than half of the cost savings achieved due to our collective efforts to be smarter in how we spend, has been reinvested in science. We strengthened our positioning in therapeutic areas through several acquisitions by adding pipeline projects where we already have a promising future. This would not have been possible without the support of all employees to the ‘Play to Win’ strategy. INTERVIEW WITH THE CHIEF Since the start of the health crisis, all our industrial sites have remained operational to maintain the continuous production of essential EXECUTIVE OFFICER medicines for patients. We have initiated two vaccine projects against COVID-19: for the most advanced of them1, the objective is to obtain approval of the health authorities in the fourth quarter of 2021 and first doses of the vaccine available for people worldwide to be ready. In the meantime, we are committed to helping some of our competitors whose vaccines have already been approved by participating in the manufacturing of millions of additional doses. -
Annual Report 2019 Contains a Full Overview of Its Corporate Stakeholder Expectations As Well As Long-Term Trends Governance Practices
Table of Contents Management report Company overview 4 Business overview 5 Disclosures about market risk 44 Group organizational structure 47 Key transactions and events in 2019 50 Recent developments 53 Research and development 54 Sustainable development 57 Corporate governance 67 Luxembourg takeover law disclosure 108 Additional information 110 Chief executive officer and chief financial officer’s responsibility statement 115 Financial statements of ArcelorMittal parent company for the year ended December 31, 2019 116 Statements of financial position 117 Statements of operations and statements of other comprehensive income 118 Statements of changes in equity 119 Statements of cash flows 120 Notes to the financial statements 121 Report of the réviseur d’entreprises agréé 170 4 Management report Company overview other countries, such as Kazakhstan, South Africa and Ukraine. In addition, ArcelorMittal’s sales of steel products History and development of the Company are spread over both developed and developing markets, which have different consumption characteristics. ArcelorMittal is the world’s leading integrated steel and ArcelorMittal’s mining operations, present in North and mining company. It results from the merger in 2007 of its South America, Africa, Europe and the CIS region, are predecessor companies Mittal Steel Company N.V. and integrated with its global steel-making facilities and are Arcelor, each of which had grown through acquisitions over important producers of iron ore and coal in their own right. many years. Since its creation ArcelorMittal has experienced periods of external growth as well consolidation Products: ArcelorMittal produces a broad range of high- and deleveraging (including through divestments), the latter quality finished and semi-finished steel products (“semis”). -
Countermotions and Proposals for Election for the Annual Stockholders’ Meeting 2021 of Bayer AG This Is a Convenience Translation
Countermotions and Proposals for Election for the Annual Stockholders’ Meeting 2021 of Bayer AG This is a convenience translation. For the legally binding document, please refer to the original German version which is published on the Internet at https://www.bayer.com/de/investoren/gegenantraege-wahlvorschlaege-hv2021. We designate with capital letters those countermotions and election proposals for which you can place a tick how you would like to vote directly under the appropriate capital letter on the reply form or in the stockholders' portal. The other countermotions, which merely reject proposals by the Board of Management and the Supervisory Board, or by the Supervisory Board alone, are not designated with capital letters. If you wish to vote for these countermotions, you must vote “No” to the respective item on the Agenda. Countermotion of Coordination gegen Bayer-Gefahren e.V. Postfach 150418, D-40081 Düsseldorf, dated April 08, 2021 Countermotion for the BAYER Annual Stockholders’ Meeting on April 27, 2021 We hereby announce that we object to the proposals of the Board of Management and the Supervisory Board with regard to Item 2 of the Agenda and intend to call on the stockholders to vote for the following countermotion. Countermotion to Agenda Item 2: The actions of the members of the Board of Management shall not be ratified For six years now, there has been a simmering legal conflict in connection with the risks and side effects of the herbicide glyphosate, which BAYER markets under the product name ROUNDUP. The company still has not been able to present a solution acceptable to all parties. -
Linde Plc Annual Report 2019
Linde plc Annual Report 2019 Form 10-K (NYSE:LIN) Published: March 18th, 2019 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________ FORM 10-K _______________________________________________ þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38730 LINDE PLC (Exact name of registrant as specified in its charter) Ireland 98-1448883 State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) The Priestley Centre, 10 Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7XY United Kingdom +44 1483 242200 (Address of principal executive offices) Registrant’s Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: Ordinary shares (€0.001 nominal value per share) New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None ___________________________________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.